Jeanne Jackson, MD
Assistant Clinical Professor of Psychiatry
Yale University School of Medicine
Alzheimer’s Resource Center
Lori Daiello, PharmD, BCPP
Geriatric Psychopharmacology Specialist
President, Pharmacotherapy Solutions
Dianne Torgersen, BSN, RNC
Director of the Dementia Unit
East Galbraith Healthcare Community
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHARMACISTS ONLY.
Developed by the American Society of Consultant Pharmacists and originally presented as a live audioconference series, this on line program is designed to assist pharmacists in understanding and implementing cognitive, behavioral, and functional assessment in elderly persons with dementia or Alzheimer’s disease. It also reviews pharmacologic and nonpharmacologic options for treatment.
Recognition and diagnosis of dementia requires a team approach in the LTC setting. Physicians can identify or rule out concomitant disorders. Pharmacists can identify patients at risk for drug-induced cognitive impairment, differentiate treatment modalities, and monitor for adverse effects and response to therapy. Nurses and CNAs bridge both fields in looking for dementia and its causes and can apply their skills in initial assessment through mental status and functional ability tests.
The faculty of this program are nationally recognized authorities on Alzheimer’s disease and dementia. We hope you will find their presentation helpful in the management of patients and residents with these debilitating conditions.
. Target Audience
This activity has been designed for consultant pharmacists and VA pharmacists who manage patients with Alzheimer’s disease and dementia in long-term care settings.
On completion of this audioconference, the participant should be able to:
Discuss the need for and implementation of methodical cognitive, behavioral, and functional assessment in the care and management of Alzheimer’s disease and dementia patients
Describe and recognize the way that Alzheimer’s disease and dementia can change the presentation of medical or psychiatric conditions
Implement team interventions to optimally care for the AD and dementia patient
Discuss the appropriate use of pharmacotherapy in this patient population
Identify potential functional, behavioral and cost outcomes of appropriate treatment
Jeanne Jackson, MD, reports receiving consultant fees for participation in Speakers Bureaus for Pfizer Inc., Eli Lilly, and Janssen Pharmaceuticals. She receives consulting fees for participation in advisory boards from Organon and Abbott Laboratories. In this program, she will be discussing off-label use of trazodone for insomnia and restlessness, and donepezil for moderate to severe Alzheimer’s disease.
Lori Daiello, PharmD reports receiving consultant fees from Eli Lilly and Company, Pfizer Inc, AstraZeneca, and Abbott Laboratories; and speaker fees and honoraria from Eli Lilly and Company, Pfizer Inc, AstraZeneca, Novartis Pharmaceuticals Corporation, Janssen Pharmaceutica Inc., Organon Inc., and Abbott Laboratories.
Ms. Torgersen reports no financial interest or other relationship with the manufacturer(s) of any commercial product(s) or service(s) discussed in this educational presentation or with commercial supporter(s) of this educational activity.
This program (#203-000-02-197-HO1) was developed by the American Society of Consultant Pharmacists (ASCP) and is approved for 1.0 Contact Hour (0.1 CEU). ASCP is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. Credit will be awarded upon submission of a completed program evaluation and a post-test with a passing grade of 70% or better.
Program Date: March, 2001. This program is valid through June 30, 2003.
Commercial Support Statements
This program was supported by an unrestricted educational grant from Pfizer, Inc and Eisai, Inc.
Click on the "Start program" icon.
The next screen will permit you to check for or download RealAudio's RealPlayer required to run this program. You will also find buttons which will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on "start the program" on this screen will begin the program presentation which will take approximately 1 hour to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CE certificate.
The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, or Pfizer, Inc and Eisai, Inc. Any medications, or other diagnostic or treatment procedures discussed by the program speaker should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.